| Prof. Dr. Michael Arand
(Professor Universität Zürich (UZH))
|Chemistry and Applied Biosciences
|Drug Discovery and Development
Only for MSc Pharmaceutical Sciences.
|1G + 2S
|J. Hall, U. Thibaut, K.‑H. Altmann, M. Arand, J. Scheuermann, R. Schibli, H. U. Zeilhofer
|This course provides an overview over the concepts and processes employed in today's drug discovery and development. It has an introductory character but will also provide more detailed insights employing real life examples. The course combines lectures and interactive elements with active participation of the students.
- Understand the drug discovery process and can explain major approaches and relevant technical terms (for details see lecture notes).
- Understand and appreciate the content and timing of drug development process steps, development phases and decision criteria.
- Understand the concepts underlying drug product development through all the phases from preclinical and clinical development to regulatory submission, approval and market launch.
- Can differentiate between small molecule drug development and biological drug development.
- Understand the most important differences for drug development and approval between the EU and USA pharma markets with regard to legal and regulatory requirements.
|Course unit comprises weekly lectures covering the early phases of target and drug discovery (535-0901-01 S "From A to Z in Drug Discovery and Development I") with group work in the area of Drug Development (511-0000-00 G). The latter course lasts 2 full days (Days 1 and 2) and comprises both lectures and group work: inter alia an introduction to the entire suite of drug product development processes in the pharmaceutical industry, covering preclinical research and development, clinical development, regulatory processes and market launch.
R&D support processes such as project management, quality management, pharmacovigilance and pharmacoeconomics will be covered as well as organizational and governance aspects of the pharmaceutical industry. In addition, important success factors for a later career in the pharmaceutical industry will be briefly discussed at the end of day 2 of the course.
|Will be published on "mystudies"
|G. Nahler (Hrsg.) Dictionary of pharmaceutical medicine, Springer, Wien, 2013 (3rd edition)
Further readings will be listed in the lecture notes.
|Prerequisites / Notice
|This course provides the essential basic knowledge required for the industry-specific modules of the spring semester.
Safety conceptt: https://chab.ethz.ch/studium/bachelor1.html
|General and Environmental Toxicology
|M. Arand, H. Nägeli
|Toxicokinetic and toxicodynamic aspects of xenobiotic interactions with cellular structures and mechanisms. Toxic responses at the level of organs (immune-, neuro-, reproductive and genotoxicity) and organisms. Introduction into developmental toxicology and ecotoxicology.
|Understanding of the impact of chemicals on biological systems; evaluation of the effects from different biomedical perspectives.
|Explanation of important interactions between xeniobiotic chemicals and cellular structures such as membranes, enzymes, and nucleic acids. Relevance of intake, distribution, excretion, and biochemical transformation processes. Relevance of mixtures. Explanation of important modes of toxic action such as immuno toxicity, neurotoxicity, reproduction toxicity, genotoxicity based on examples of certain xenobiotics and their effects on important organs.
|Course material will be handed out as the lectures progress
|Textbooks of pharmacology and toxicology (cf. list in course material)
|Prerequisites / Notice
|Educational basis: basic chemistry, biology and biochemistry
|Pharmacology and Toxicology III
|U. Quitterer, M. Arand, Y. Yamauchi
|The course is divided into two parts. The first part provides a detailed understanding of drugs and the pharmacotherapy of infectious diseases and cancer. The second part gives an overview of the field of pharmacogenomics and toxicogenomics with a special focus on the role of genetic polymorphisms in disease susceptibility, drug response and adverse effects.
|The course advances basic knowledge in pharmacology and toxicology. Special emphasis is placed on the interrelationship between pharmacological, pathophysiological and clinical aspects of drug therapy in the fields of infectious diseases and cancer. The course also provides an overview of the field of pharmacogenomics and toxicogenomics, with a special focus on the role of genetic polymorphisms in disease susceptibility, drug response and adverse effects.
|Topics include the pharmacology and pharmacotherapy of infectious diseases and cancer. In the field of pharmacogenomics and toxicogenomics, the course is focused on genetics, genome-wide association studies, examples of genetic variability of drug metabolism and drug responses, and the relevance of pharmacogenomics and toxicogenomcis for clinical drug development.
|A script is provided for each lecture. The scripts define important and exam-relevant contents of the lectures. Scripts do not replace the lectures.
The classic textbook in Pharmacology:
Goodman and Gliman`s The Pharmacological Basis of Therapeutics
Laurence Brunton, Bjorn Knollman, Randa Hilal-Dandan.
13th edition (2017)
or 14th edition (expected Oct. 2022)
Klaus Aktories, Ulrich Förstermann, Franz Hofmann, Klaus Starke.
Allgemeine und spezielle Pharmakologie und Toxikologie.
12th edition (2017)
Urban & Fischer (Elsevier, München)
|From A to Z in Drug Discovery and Development
|J. Hall, K.‑H. Altmann, M. Arand, J. Scheuermann, R. Schibli, H. U. Zeilhofer
|The lecture series takes place at the ETH Hönggerberg and covers a variety of major activities involved in drug discovery: selecting drug targets, technologies used in drug discovery, small, medium and large drugs, objectives of the medicinal chemist, assessing drug safety, principles of personalized medicine, designing clinical trials, how intellectual property is protected, as well as others.
|The objective of the course is to gain a global understanding of most of the important phases in the discovery and development of modern synthetic and biological drugs, from the first activities to clinical trials. The lecture is intended for students that have an interest in the area and/or may consider a career working in drug discovery. This lecture course complements knowledge and experience gained in the research project performed by the PhD student.
|Thirteen two hour lectures for life-science PhD students and students of the Pharmaceutical Sciences Master, given by experts from the ETH, UZH, USZ and the pharmaceutical industry.
Introduction to the modern drug discovery process - Principles of drug pharmacokinetics and drug metabolism - Computer sciences in drug discovery - Drug targets - In vitro methods in drug discovery - Natural products in drug discovery - Medicinal chemistry: Chemical lead selection/optimization - Antibodies and therapeutic proteins: Targets and drugs - In vivo molecular imaging in drug discovery - Drug formulation: Key development consideration, Current new APIs challenges and FDA rising standards - Preclinical safety, adverse drug events and drug-drug interactions - Clinical development steps including trial design - Intellectual property in drug discovery and development
|Scripts to be uploaded into ILIAS
|To be distributed during the lecture
|Prerequisites / Notice
|Formally none, but a basic understanding in biochemistry, physiology and chemistry is highly desirable as it will certainly help to get the most from the lectures.